CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
“跳出”生发中心“思考：重新教育 T 细胞以对抗滤泡性淋巴瘤
英文原题：Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
查看英文原题
Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
滤泡性淋巴瘤（FL）是最常见的惰性淋巴瘤，其治疗近年取得显著进展，包括免疫调节剂来那度胺、表观遗传调节剂他泽司他，以及磷脂酰肌醇3激酶抑制剂可泮利塞。本综述聚焦T细胞衔接疗法，包括嵌合抗原受体（CAR）T细胞和双特异性抗体；这些疗法近期改变了FL治疗格局。两种CAR-T 细胞产品——阿基仑赛（axi-cel）和替沙仑赛（tisa-cel）——以及一种双特异性抗体莫妥珠单抗，近期获FDA批准用于FL。另有多种新型免疫效应药物正在评估，将进一步扩充治疗选择。本文重点讨论CAR-T 细胞和双特异性抗体疗法，详述其安全性和疗效，并分析其在当前FL治疗中的发展作用。
展开英文摘要原文
There have been significant advancements in the management of follicular lymphoma (FL), the most common indolent lymphoma. These include immunomodulatory agents such as lenalidomide, epigenetic modifiers (tazemetostat), and phosphoinotiside-3 kinase inhibitors (copanlisib). The focus of this review is T cell-engager therapies, namely chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, have recently transformed the treatment landscape of FL.
Two CAR T cell products, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), and one bispecific antibody, mosunetuzumab, recently received FDA approvals in FL. Several other new immune effector drugs are being evaluated and will expand the treatment armamentarium. This review focuses on CAR T-cell and bispecific antibody therapies, details their safety and efficacy and considers their evolving role in the current treatment landscape of FL.
论文信息
- 作者
- Thiruvengadam SK、Shouse G、Danilov AV
- 第一作者单位
- City of Hope National Medical Center, Duarte, CA, USA.United States
- 通讯作者单位
- City of Hope National Medical Center, Duarte, CA, USA. Electronic address: adanilov@coh.org.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Blood reviews2023 Sep
- 原文标识
- PubMed 37173225 · DOI 10.1016/j.blre.2023.101099